Bladder Cancer

Information on Bladder Cancer

[Bladder Cancer @BladderCa]

Cytotoxic CD4+ T Cells in Bladder Cancer-A New License to Kill.
#BladderCancer #UroToday
https://t.co/ywJeBBjtso

[Bladder Cancer @BladderCa]

Upregulation of lncRNA plasmacytoma variant translocation 1 predicts poor prognosis in patients with muscle-invasive bladder cancer.
#BladderCancer #UroToday
https://t.co/uEHkH4bwLE

[Bladder Cancer @BladderCa]

Bladder Cancer in Times of COVID-19 in India - Pradeep P. Rao #BladderCancer #UroToday
https://t.co/TMwS5YbTJn

[Bladder Cancer @BladderCa]

TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. #BladderCancer #UroToday
https://t.co/iel79GFaYi

[Bladder Cancer @BladderCa]

Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer. #BladderCancer #UroToday
https://t.co/oqxiiqstBp

[Bladder Cancer @BladderCa]

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. #BladderCancer #UroToday
https://t.co/DwSYKLJEly

[Bladder Cancer @BladderCa]

UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma.
#BladderCancer #UroToday
https://t.co/8MEt30IIt9

[Bladder Cancer @BladderCa]

EAU 2020: Five Things I Wish I Would Have Known Earlier in My Career: Lessons from the Mentors - Bladder Cancer
#BladderCancer #UroToday
https://t.co/hQjzV1FSNw

[Bladder Cancer @BladderCa]

Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer. #BladderCancer #UroToday
https://t.co/IMKBo0jDjc

[Bladder Cancer @BladderCa]

Bladder cancer incidence rates and trends in young adults aged 20-39 years. #BladderCancer #UroToday
https://t.co/3PV9LisQTa

[Bladder Cancer @BladderCa]

The Cancer of the Bladder Risk Assessment (COBRA) score for Estimating Cancer-Specific Survival after Radical Cystectomy: External Validation in a Large Bi-institutional Cohort. #BladderCancer #UroToday
https://t.co/O35kfiD6El

[Bladder Cancer @BladderCa]

Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study. #UroToday #BladderCancer
https://t.co/VbLv8W5v7Y

[Bladder Cancer @BladderCa]

Biopsy at flexible cystoscopy: is it worthwhile? #UroToday #BladderCancer
https://t.co/04ZnsDL7sA

[Bladder Cancer @BladderCa]

Urobiome in Gender-Related Diversities of Bladder Cancer. #BladderCancer #UroToday
https://t.co/bQsomX3MR0

[Bladder Cancer @BladderCa]

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. #BladderCancer #UroToday
https://t.co/D78upAC4cO

[Bladder Cancer @BladderCa]

The emerging role of antibody-drug conjugates in urothelial carcinoma. #BladderCancer #UroToday
https://t.co/g0C9XKnyjZ

[Bladder Cancer @BladderCa]

FDA Approves Avelumab as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma #BladderCancer #UroToday
https://t.co/HII2oRPAb0

[Bladder Cancer @BladderCa]

The RESECT Study: Improving Quality in TURBT Surgery - Veeru Kasivisvanathan #BladderCancer #UroToday
https://t.co/n3TmoJZDAP

[Bladder Cancer @BladderCa]

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer #BladderCancer
https://t.co/tyXcF0zNxz

[Bladder Cancer @BladderCa]

AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive) - Joshua Meeks and Sima Porten #BladderCancer #UroToday
https://t.co/gKHGihwTN2